Improvement of atopic dermatitis and alopecia universalis with dupilumab: a case report [PDF]
Dermatology Reports, 2021 Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that showed significant improvement of atopic dermatitis (AD). Many reports have shown significant resolution of alopecia areata, alopecia universalis, and alopecia totalis after dupilumab ...
Lama Alotaibi +3 more
doaj +2 more sources
JAMA Dermatol, 2023 Importance Prevalences of alopecia areata (AA), alopecia totalis (AT), and alopecia universalis (AU) are poorly established. Objective To estimate overall and subgroup prevalences of AA and its subtypes.
Sy N, Mastacouris N, Strunk A, Garg A.
europepmc +2 more sources
A Case Series and Literature Review of Telogen Effluvium and Alopecia Universalis after the Administration of a Heterologous COVID-19 Vaccine Scheme. [PDF]
Vaccines (Basel), 2023 COVID-19 vaccines have positively changed the course of the pandemic. They entered the market after only one year of the initial trials, which that yielded positive results in terms of safety and efficacy. However, after inoculating billions of people in
Hernández Arroyo J +2 more
europepmc +2 more sources
Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review. [PDF]
Acta Derm Venereol, 2023 is missing (Short communication)
Yu D, Ren Y.
europepmc +2 more sources
Viral-Induced Rapidly Progressive Alopecia Universalis: A Case Report and Literature Review. [PDF]
Cureus, 2023 Alopecia areata is a common autoimmune condition that causes a non-scarring form of hair loss. It is associated with several viruses and diseases. One of the viruses that have been linked to alopecia areata is the coronavirus disease of 2019 (COVID-19 ...
Alotaibi MA +3 more
europepmc +2 more sources
Hair regrowth and maintenance in alopecia universalis patient treated with nonablative Er:YAG laser [PDF]
Clinical Case Reports, 2021 Hair regrowth with no adverse effects following nonablative 2940‐nm Er:YAG laser treatment in alopecia universalis patient resulted in high patient satisfaction and compliance. As the main challenge in alopecia universalis is maintenance of regrown hair,
Madison McCarthy, Doris Day, Iva Talaber
doaj +2 more sources
Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis. [PDF]
Ther Adv Neurol Disord, 2022 Herein, we report a case of alopecia universalis and transient accommodation spasm presented after alemtuzumab administration in a patient previously treated with fingolimod.
Tzanetakos D +10 more
europepmc +2 more sources
Schizophrenia in a case of alopecia universalis
Annals of Indian Psychiatry, 2017 Alopecia universalis is characterized by total loss of hair from all over the body such as the scalp, eyebrows, and limbs. Alopecia areata has been known to coexist with psychiatric disorders such as anxiety disorders and depression, although reports ...
Deepa Sangolkar +4 more
doaj +2 more sources
Alopecia Universalis Successfully Treated With Adalimumab [PDF]
JAMA Dermatology, 2014 IMPORTANCE Alopecia universalis is an uncommon form of alopecia areata (AA) involving hair loss over the entire scalp and body and is often difficult to treat. Tumor necrosis factor (TNF)inhibitors have been largely unsuccessful in treating AA and have been reported to induce or worsen AA in patients.We report herein a case of alopecia universalis ...
Loren Gorcey +2 more
openalex +4 more sources
Alopecia Universalis following Alemtuzumab Treatment in Multiple Sclerosis: A Barely Recognized Manifestation of Secondary Autoimmunity—Report of a Case and Review of the Literature [PDF]
Frontiers in Neurology, 2017 Secondary autoimmunity is the most frequent adverse event occurring in almost every other alemtuzumab-treated multiple sclerosis patient. We report a case of a patient with relapsing-remitting multiple sclerosis who reported smooth, circular areas of ...
Julian Zimmermann +2 more
doaj +2 more sources